CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Infineon Technologies AG (IFX.DE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Infineon Technologies AG (IFX.DE)

Biotechnology · market cap $58.5B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
0
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Infineon Technologies AG (IFX.DE) is classified under the Biotechnology sector in the provided data, with approximately 57,077 employees and a market capitalization of roughly $58,510M. However, the facts supplied contain no lead asset, no pipeline, no upcoming catalysts, no financial detail, and no analyst coverage — rendering a substantive dossier impossible from the available data.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline

No pipeline data.

Price & technical context
3-month
+15.0%
6-month
+8.8%
12-month
+12.2%
52-wk range
$24.34–$38.66
vs 50-day MA
+7.6%
vs 200-day MA
+9.4%
Realized vol
38.7%
Max drawdown
-37.0%

Daily closes through 2025-12-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for IFX.DE (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.